Researchers have elucidated the role of HP1 proteins in relation to chromatin structure and genome stability. The study shows that different HP1 isoforms play distinct roles in regulating chromatin domains.
Researchers have successfully tested a new molecule capable of preventing peripheral neuropathy induced by chemotherapy in cancer patients. The molecule has shown positive results in reducing the appearance of disorders associated with nerve dysfunction.
Researchers have identified a new genetic marker, BRF1, associated with up to 1.4% of hereditary colon cancer cases. The finding allows for personalized follow-up programs and potential prevention of early onset cancer in mutation carriers.
Researchers have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment, making them tolerant to cancer cells. The study found that DNA methyltransferase 3A is responsible for the acquisition of suppressive properties in these cells.
A Phase II clinical trial found that an injectable antiretroviral treatment was as effective as standard oral therapy in suppressing viral loads in HIV patients. The treatment, which involves a combination of carbotegravir and rilpivirine injected every 4 or 8 weeks, showed improved adherence rates and quality of life for patients.
The EPICUP® test, based on DNA analysis, can correctly diagnose CUP in 70% of cases, increasing the detection rate from traditional methods' 30%. This leads to the development of more specific treatments for these patients.
A new study suggests that D-serine, a dietary supplement, improves neuronal function in a patient with atypical Rett syndrome. The treatment, which was developed using personalized algorithms, has shown promising results in improving motor and cognitive symptoms.
A new mechanism has been identified by researchers where a subset of free 40S ribosomes preserve genetic information needed to produce new ribosomes. This discovery may lead to new therapies for cancer and 5q- syndrome, conditions where cancer cells exploit ribosome biogenesis to proliferate.
A research team from IDIBELL has characterized the complete epigenomes of the most frequent tumors, including those of colon, lung and breast cancer. The study reveals that anti-cancer genes slow down their activity in cancer-affected organs, but also identifies alterations in distant chromosomal regions.
Researchers have characterized the unusual cell death process triggered by starvation, where the endoplasmic reticulum plays a key role. This discovery may shed new light on tumor progression and ischemia-related cell death in cancer and other diseases.
Researchers have identified a genetic signature associated with resistance in triple negative breast cancer, which can be reversed after a period of treatment cessation. This discovery may lead to personalized chemotherapy strategies and improved treatment outcomes.
A study published in Leukemia reveals an epigenetic lesion that correlates with the activation of a powerful oncogene capable of malignizing lymphocytes, leading to acute T-cell leukemia. The research suggests that targeting this gene may offer new treatment options for patients with this aggressive type of cancer.
The TGF-beta cytokine modulates hepatocellular carcinoma cell migration and tumor initiator capacity. The study reveals a dual role of TGF-beta in cancer, acting as both a suppressor and enhancer.
The epitranscriptome, a newly discovered regulatory layer of RNA, shows promise in understanding human diseases. Recent research reveals that RNA modifications play a crucial role in controlling its stability and function.
Researchers developed a predictive risk model combining genetic and lifestyle information to classify population into groups according to colon cancer risk. Lifestyle influences cancer risk more than genetics, making it a modifiable factor in disease prevention.
Researchers at IDIBELL have developed an oncolytic virus that redirects the patient's immune system against tumor cells, increasing antitumor efficacy. The virus uses BiTE antibodies to activate T lymphocytes and capture them to attack adjacent cancer cells.
Researchers found that S6K1 phosphorylation mediates the transport of fatty acids, contributing to adiposity and aging. Mice with deficient EPRS showed similar physical characteristics to those with deficient S6K1, suggesting a dual role for S6K1 in obesity.
The EurOPDX consortium develops patient-derived xenografts to replicate tumor behavior in mice, enabling personalized medicine and drug assessment. Researchers aim to validate multicentric preclinical studies using these models, increasing the efficiency of cancer research and treatment.
The study identified inactivating mutations in the B2M gene, which codes for a protein involved in the immune response. In lung cancer patients, higher levels of B2M expression correlate with improved response to immunotherapy.
Researchers found that NOX4 inhibits epithelial-amoeboid transition, a process contributing to liver cancer progression. Low expression of NOX4 is associated with poor prognosis and high Rho protein expression.
IDIBELL researchers describe the Ewing's sarcoma methylation profile for the first time, unveiling the potential of the PTRF gene as a prognostic marker and possible future therapeutic target. The study found that PTRF expression is associated with better survival rates in patients.
Researchers found that a new triple regimen of integrase inhibitor Dolutegravir decreases viral load in semen very quickly, reducing the risk of HIV sexual transmission. This treatment approach could potentially shorten previous antiretroviral prophylaxis.
Researchers analyzed brain activity in people with musical anhedonia, finding reduced activity in the nucleus accumbens. This suggests a link between music processing and reward system, highlighting its evolutionary importance.
Researchers at IDIBELL have found a common cause of multiple resistance in cancer chemotherapy, highlighting the loss of TP53TG1 molecule as a key driver. This discovery has significant implications for understanding treatment failure and may lead to new therapeutic strategies to overcome chemoresistance.
Researchers have identified HDAC7 as a transcriptional repressor involved in B lymphocyte generation and identity. The study reveals that HDAC7 is essential for B cell development, maintaining its lymphoid identity by silencing lineage-inappropriate genes.
Researchers found that pharmacological and genetic RANK pathway inhibition significantly reduced recurrences and metastases in a mouse animal model of breast cancer. This suggests RANK inhibitors used in osteoporosis treatment may also be effective against breast cancer.
Researchers at IDIBELL discovered that tumor microenvironment triggers processes to protect tumor cells from conventional chemotherapy. The presence of certain molecules slows down cell cycle and activates proteins minimizing treatment effectiveness.
A new orthotopic animal model has been created to study metastasis in Ewing sarcoma, allowing researchers to replicate the primary tumor's growth environment. The model provides valuable insights into metastatic processes and may become a tool for analyzing metastatic potential in other sarcomas.
A new epigenetic test can diagnose the primary tumor responsible for metastasis in patients with Cancer of Unknown Primary (CUP), allowing for more specific treatments. This test, EPICUP, analyzes a patient's DNA to identify the type of cancer, resulting in improved survival rates.
Researchers found that colorectal tumors have different regions with varying levels of epigenetic changes, which relate to the tumor's growth rate and aggressiveness. This heterogeneity can be used to predict prognosis and treatment resistance.
Researchers created a comprehensive map of genetic and epigenetic lesions in human tumors, predicting responses to various cancer drugs. The study integrated 1,000 tumor cell lines with genetic, epigenetic, and expression alterations, validating results in 11,000 additional human samples.
Autoinflammatory diseases are characterized by recurrent acute inflammatory episodes due to deregulation of the inflammatory process. Researchers have identified epigenetic alterations in cryopyrin-associated periodic syndromes (CAPS), which could lead to the development of novel biomarkers for diagnosis and treatment.
Dr. Manel Esteller receives top-funding European grant to develop ncRNA DNA Methylation Kit for Cancer of Unknown Primary treatment. The kit aims to improve clinical management and patient outcomes by providing personalized treatment suggestions.
Researchers found that inhibiting the p110α PI3K isoform is sufficient to block tumor growth and metastasis in a mice model of pancreatic neuroendocrine tumors. The study demonstrates promise for a new targeted therapy, with potential benefits including reduced toxicity compared to generic inhibitors.
Researchers from IDIBELL-Bellvitge Biomedical Research Institute have found that combining a positive emotional component with a given stimulus promotes memory for future stimuli of the same type. This effect is observed until after 24 hours of sleep, when memory consolidation is maximized.
A recent study published in Oncogene reveals that alterations in an intermediate molecule called RNA can lead to protein mutations without DNA damage. This discovery highlights the importance of RNA editing enzyme ADAR1 in regulating gene expression and contributing to tumor growth.
A study of 30 patients found that surgery effectively controlled hypercalcemia, normalized parathyroid hormone levels, and improved bone density. In contrast, medication only controlled excess calcium in 67% of cases, with no effect on PTH or slowing the decline in bone density.
Late-treatment HIV patients with low CD4 levels progress to AIDS at high rates if immune response isn't recovered. However, if viral load is undetectable and CD4 counts rise above 200, mortality and progression decrease.
A team of researchers has developed a C. elegans worm model with mutations that cause Retinitis pigmentosa, a rare blindness subtype affecting over 1 million people worldwide. The study reveals the disease's specificity in the retina and proposes a new hypothesis based on genomic instability.
Researchers identified a connection between DNMT3A gene mutations and the activation of oncogene MEIS1, which induces acute myeloid leukemia. The study found that this subtype of leukemia may be sensitive to drugs targeting both genes.
A licensed technology measures anti-HLA antibody secretion from memory B cells, improving kidney transplant efficiency and preventing rejection. Researchers found high-risk patients using this technique, which complements existing antibody measurement methods.
Scientists have discovered a mutated gene, JMJD1C, responsible for cases of unknown origin intellectual disability and autism. The study analyzed the genome of 215 patients with these conditions and found that this gene contributes to Rett syndrome.
Researchers have found a potential treatment option for children with Ewing's sarcoma by combining two active ingredients, Olaparib and Trabectedin, which achieves complete remission in all cases. The combination enhances the sensitivity of cancer cells to these drugs, increasing its effect.
Researchers have discovered a potential target for the treatment of type 2 diabetes by inhibiting the S6K1 protein, which increases insulin sensitivity in mice. In animal models, S6K1 deficient mice displayed improved insulin response and reduced risk of developing diabetes.
Researchers identified epigenetic alterations in CVID patients by comparing monozygotic twins. They found higher DNA methylation levels and impaired DNA demethylation in immunodeficient B cells, leading to reduced antibody production and altered cell maturation. These findings provide new insights into the diagnosis and treatment of CVID.
Researchers have found evidence of a potential sixth DNA base, methyl-adenine (mA), in complex organisms including humans, algae and worms. This discovery could have significant implications for our understanding of epigenetics and gene regulation.
Researchers at IDIBELL have discovered a molecular mechanism that explains how antisense DNA transcripts regulate gene expression in cancer. The findings provide new clues and mechanisms to understand the functions and alterations of these transcripts in cancer, including their role in tumor invasion.
Researchers at IDIBELL have created new mouse models for studying neurofibromatosis type 1, a rare genetic disorder. The models, which reproduce human tumor characteristics, enable the prediction of tumor development and treatment decisions.
A study by Genes and Cancer group at Bellvitge Biomedical Research Institute found that the inactivation of PARD3 gene promotes tumor cell invasion and metastasis in lung cancer. Restoring PARD3 levels significantly reduced the risk of metastasis in animal models.
Researchers suggest inhibition of Sirtuin1 protein as a future treatment option for metastatic Ewing sarcoma. The study found overexpression of sirtuin 1 significantly correlated with metastasis in patient samples, opening the door to treatment of aggressive tumors.